Nico Gagelmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the results from the meta-analysis evaluating the outcomes of anti-BCMA CAR T-cell therapy in relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).